The problem of viral escape is a major challenge for those attempting to control an ongoing HIV-1 infection with AAV-delivered transgenes. This problem can be addressed by anticipating and blocking viral escape pathways. Alternatively one can target unvarying cellular proteins. In Project 4, we determine if antibodies targeting two HIV-1 coreceptors, CCRS and CXCR4, can safely control HIV-1 replication. MSM Protein Technologies, Inc. has proprietary technology for developing fully human antibodies that can recognize any CCRS or CXCR4 epitope, and for further improving these antibodies to obtain affinities in the picomolar range. We have generated antibodies against a range of chemokine receptors, using technology that we originally developed to study CCRS and CXCR4. However, antibodies recognizing chemokine receptors can interfere with appropriate immune function. It is therefore critical that antibodies targeting CCRS or CXCR4 are not themselves receptor agonists, and that anti-CXCR4 antibodies do not interfere with chemotaxis or signaling mediated by the CXCR4 ligand CXCL12/SDF-1a. We will therefore: 1) generate and characterize sets high affinity antibodies specific for CCRS, recognizing distinct and noncompeting epitopes, which do not agonize the receptor, but which efficiently inhibit HIV-1 infection. 2) determine if heterodimeric forms of these anti-CCRS antibodies more effectively neutralizing HIV-1 than any individual anti-CCRS antibody. 3) develop and improve an anti-CXCR4 antibody that efficiently inhibits replication of X4 and RSX4 HIV-1 isolates, but which does not compete with SDF1a binding to CXCR4. 4) evaluate the ability of these antibodies, delivered as AAV expressed transgenes, to control ongoing SHIV infections in rhesus macaques.
These aims will generate several very high affinity anti-CCRS and -CXCR4 antibodies that potently neutralize HIV-1 infection, and establish their ability to control viral replication in vivo.

Public Health Relevance

Recombinant AAV-delivered transgenes have the potential to supplement or even replace conventional combination anti-HIV-1 therapies, and have considerable advantages over these therapies. This project will evaluate the therapeutic utility of transgenes that target the obligate HIV-1 coreceptors CXCR4 and CCRS. In doing so, we will evaluate one approach for limiting viral escape from expressed transgenes, and develop therapeutics that can be used in human clinical trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Florida
United States
Zip Code
Wang, Dan; Li, Jia; Song, Chun-Qing et al. (2018) Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nat Biotechnol 36:839-842
Fetzer, Ina; Gardner, Matthew R; Davis-Gardner, Meredith E et al. (2018) eCD4-Ig Variants That More Potently Neutralize HIV-1. J Virol 92:
Yoon, Yeonsoo; Wang, Dan; Tai, Phillip W L et al. (2018) Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. Nat Commun 9:412
Zhang, Wei; Li, Linjing; Su, Qin et al. (2018) Gene Therapy Using a miniCEP290 Fragment Delays Photoreceptor Degeneration in a Mouse Model of Leber Congenital Amaurosis. Hum Gene Ther 29:42-50
Tai, Phillip W L; Xie, Jun; Fong, Kaiyuen et al. (2018) Adeno-associated Virus Genome Population Sequencing Achieves Full Vector Genome Resolution and Reveals Human-Vector Chimeras. Mol Ther Methods Clin Dev 9:130-141
Mou, Huihui; Zhong, Guocai; Gardner, Matthew R et al. (2018) Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. Mol Ther 26:1277-1286
Wang, Dan; Gao, Guangping (2018) Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. Mol Ther 26:336-338
Wang, Dan; Li, Jia; Tran, Karen et al. (2018) Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. Hum Gene Ther Methods 29:75-85
Wang, Dan; Li, Shaoyong; Gessler, Dominic J et al. (2018) A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Mol Ther Methods Clin Dev 9:234-246
Lu, Yi; Tai, Phillip W L; Ai, Jianzhong et al. (2018) Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs. Mol Ther Nucleic Acids 10:349-360

Showing the most recent 10 out of 46 publications